RT Journal Article
SR Electronic
T1 Post-COVID-19 syndrome and insulin resistance 20 months after a mild COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.17.23288637
DO 10.1101/2023.04.17.23288637
A1 Fierro, Patricia
A1 Martín, David
A1 Pariente, Emilio
A1 García-Garrido, Ana B
A1 Basterrechea, Héctor
A1 Petitta, Benedetta
A1 Bianconi, Camila
A1 Herrán, Sara
A1 Berrueta, Andrea
A1 Jorrín, Ascensión
A1 Gómez, Alicia
A1 Casado, Raquel
A1 Cuadrado, Alfredo
A1 Ramos, Carmen
A1 Hernández, José L
YR 2023
UL http://medrxiv.org/content/early/2023/04/19/2023.04.17.23288637.abstract
AB Objective SARS-CoV-2 infection is associated with impaired glucose metabolism. Although the mechanisms are not fully understood, insulin resistance (IR) appears to be a central factor. Patients who had a severe acute phase, but even asymptomatic or with mild COVID-19, have an increased risk of T2DM. After the acute phase, post-COVID-19 syndrome (PCS) also seems to be related to this metabolic disturbance, but there is a paucity of studies. This study aims to evaluate a possible relationship between PCS and IR after mild COVID-19 and, if confirmed, whether there are differences by sex.Subjects and methods Retrospective observational cohort study including subjects who had mild COVID-19 between April and September 2020 in a community setting. None had been vaccinated against SARS-CoV-2 at inclusion, and previous T2DM and liver disease were exclusion criteria. Patients who met NICE criteria were classified as PCS+. Epidemiological and laboratory data were analysed. Three assessments were performed: 1E (pre-COVID-19, considered baseline and reference for comparisons), 2E (approximately 3 months after the acute phase), and 3E (approximately 20 months after the acute phase).A triglyceride-to-glucose (TyG) index ≥8.74 was considered IR. Albumin-to-globulin ratio (AGR) and lactate dehydrogenase (LDH) were assessed as inflammatory markers. Bivariate analyses were performed, using nonparametric and repeated measures tests.A subsample without metabolic disorder or CVD (age<median, BMI<25 kg/m2, elevated AGR, TyG index=7.80 [0.5]) was generated to reasonably rule out prior baseline IR that could bias the results. The relationships between PCS and TyG in 3E (TyG3) were modeled in 8 multiple regressions, stratifying by sex and BMI combinations.Results A total of 112 subjects (median [IQR] of age= 44 [20] years; 65 women) were analysed. Up to 14.3% was obese and 17% was hypertensive. Significant increases between 1E and 3E were registered regarding (i) basal glycemia (BG), 87 [14] mg/dL vs. 89 [14]; p=0.014, (ii) TyG index (8.25 [0.8] vs. 8.32 [0.7]; p=0.002), and (iii) LDH in 3rd tertile (16.1% vs 32.1%; p=0.007). A total of 8 previously normoglycemic subjects, showed BG2 or BG3 >126 mg/dL.The subgroups with IR highest prevalence at 3E were those of BMI ≥25 kg/m2 and PCS+. The subgroup without CVD presented a significant increase in the TyG index (TyG1=7.80 [0.1] vs. TyG3= 8.28 [0.1]; p=0.017). LDH1 was significantly correlated with TyG3 in both sexes (rho=0.214 in women, rho=0.298 in men); in contrast, LDH2 and LDH3 did not present such an association.In multivariable analysis, PCS has shown to be an independent and predictive variable of TyG index in women with BMI<25 kg/m2, after adjustment for age, hypertension, BMI, Charlson comorbidity index, AGR1, AGR2, LDH1, number of symptoms of acute COVID-19, and number of days of the acute episode (β=0.350; p=0.039).Conclusions PCS has played a secondary role in predicting IR, showing a modest effect compared to BMI or prior hypertension. A significant increase in IR has been noted 20 months after mild COVID-19, both in cases of previous baseline IR and in those without previous IR. Basal serum LDH has shown to be predictive of current TyG, regardless of elevated LDH after SARS-CoV-2 infection. There were profound differences between women and men, confirming the need for a sex-stratified analysis when addressing the relation between PCS and glycemic alterations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Clinical Research Ethics Committee of Cantabria (code 2021.102)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsACE2Angiotensin converting enzyme-2AGRAlbumin-to-globulin ratioBGBasal glycemiaBMIBody mass indexCCICharlson comorbidity indexCRPC-reactive proteinCVDCardiovascular diseaseIFLInterferon gammaIGF-1Insulin growth factor-1IL-1βInterleukin-1βIL-6Interleukin-6IRInsulin resistanceISInsulin sensitivityLDHLactate dehydrogenaseMetSMetabolic syndromeNLRNeutrofil-to-lymphocyte ratioPCSPost-COVID-19 syndromeTNFαTumor necrosis factor AlphaTyG indexTriglyceride glucose indexT2DMType 2-diabetes mellitus